# Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

> **NCT03971409** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Laura Huppert, MD, BA** · enrollment: 145 (actual)

## Conditions studied

- Stage III Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Stage IV Breast Cancer
- Invasive Breast Carcinoma
- Recurrent Breast Carcinoma
- Triple-Negative Breast Carcinoma
- Unresectable Breast Carcinoma

## Interventions

- **BIOLOGICAL:** Anti-OX40 Antibody PF-04518600
- **DRUG:** Avelumab
- **DRUG:** Binimetinib
- **BIOLOGICAL:** Utomilumab
- **DRUG:** Liposomal Doxorubicin
- **DRUG:** Sacituzumab Govitecan

## Key facts

- **NCT ID:** NCT03971409
- **Lead sponsor:** Laura Huppert, MD, BA
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-07-08
- **Primary completion:** 2027-01-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2026-04-17

## Collaborators

- Translational Breast Cancer Research Consortium
- Hoosier Cancer Research Network
- Array BioPharma
- Pfizer
- Breast Cancer Research Foundation
- Johns Hopkins University
- Gilead Sciences

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03971409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03971409, "Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03971409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*